Olene Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.19 M
as on 16-11-2024
- Company Age 9 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.00 Cr
as on 16-11-2024
- Revenue -0.33%
(FY 2023)
- Profit 18.97%
(FY 2023)
- Ebitda -19561.26%
(FY 2023)
- Net Worth -3.04%
(FY 2023)
- Total Assets 5.80%
(FY 2023)
About Olene Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.19 M.
The company currently has active open charges totaling ₹3.00 Cr.
Vivekanand Parachur and Somashekara Nirvanashetty serve as directors at the Company.
- CIN/LLPIN
U74999TN2015PTC102820
- Company No.
102820
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Oct 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Olene Life Sciences Private Limited offer?
Olene Life Sciences Private Limited offers a wide range of products and services, including Medical Surgery & Treatment Centres, Medical Treatment Services.
Who are the key members and board of directors at Olene Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vivekanand Parachur  | Director | 30-Oct-2015 | Current |
| Somashekara Nirvanashetty | Director | 30-Oct-2015 | Current |
Financial Performance and Corporate Structure Insights of Olene Life Sciences.
Olene Life Sciences Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 0.33% decrease. The company also saw a substantial improvement in profitability, with a 18.97% increase in profit. The company's net worth dipped by a decrease of 3.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Olene Life Sciences?
In 2023, Olene Life Sciences had a promoter holding of 51.66% and a public holding of 48.34%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Overseas Bank Creation Date: 06 Aug 2024 | ₹3.00 Cr | Open |
How Many Employees Work at Olene Life Sciences?
Unlock and access historical data on people associated with Olene Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Olene Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Olene Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
